Magnus Group is pleased to announce one of its kind “International conference on Orphan Drugs and Rare Diseases” during August 17-19, 2023. Orphan Drugs 2023 is scheduled in Virtual Format: You can participate Virtually from your home or workplace.
The conference will maintain its unique theme “Orphan drugs: Ray of hope for rare disease”.
A rare disease is described by the World Health Organization as a disease or disorder that affects one in every 1000 people. However, rare diseases are not so rare these days. These diseases have grabbed the attention of the pharmaceutical industry and scientists over the past three decades.
Orphan drugs are medications or vaccines that are used to treat, prevent, or diagnose a rare disorder (such as Huntington's disease, Tourette syndrome or myoclonus). These drugs are called orphan because of their rarity, without government funding it would be unprofitable to manufacture these drugs. Orphan drug production for rare diseases is rife with opportunities and obstacles on a global scale, including regulatory strategies, research and development, clinical trials, time to reach market, and affordability and accessibility disparities. It is timely that experts from academia and industry unite and address these issues that will steer the development of orphan drugs.
This global congress on Orphan drugs and rare diseases provides a head interdisciplinary stage for experts to introduce their most recent research findings and portray developing advances and bearings in rare diseases. Orphan Drugs 2023 attempts to contribute to presenting novel research results in all aspects of Orphan Drugs and Rare Diseases and address the hardships faced by the scientific community from its development to its marketing.
This Congress will bring experts from the whole value chain under one roof, where you get to meet decision-makers in the areas of your interest and collaborate with them for future research. The conference aims to bridge the gap between industry and academia by uniting biotechnologists, scientists, researchers, doctors, orphan drug developers, professors, research organizations, experts from pharma industry, startups and key players in the industry.